Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GDTC

CytoMed Therapeutics Ltd

May 01 • 04:00PM ET

2.14

Dollar change +0.03
Percentage change 1.42	%

Healthcare • Biotechnology • Singapore • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	65.68%	Shs Outstand	11.53M	Perf Week	-0.47%
Market Cap	24.67M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.96M	Perf Month	2.88%
Income	-3.08M	PEG	-	EPS next Q	-	Inst Own	0.04%	Short Float	0.99%	Perf Quarter	-39.55%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.54	Perf Half Y	-38.26%
Book/sh	0.74	P/B	2.89	EPS next Y	-	ROA	-46.37%	Short Interest	0.04M	Perf Year	-37.61%
Cash/sh	0.59	P/C	3.62	EPS next 5Y	-	ROE	-68.68%	52W Range	1.92 - 9.25	Perf YTD	-56.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-34.84%	52W High	-76.86%	Beta	0.65
Dividend TTM	-	Quick Ratio	14.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.46%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	14.08	EPS Y/Y TTM	-90.04%	Oper. Margin	0.00%	RSI (14)	48.95	Volatility	3.35% 3.24%
Employees	34	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	9.49%	Payout	-	Rel Volume	0.02	Prev Close	2.11
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 17 BMO	Avg Volume	25.52K	Price	2.14
SMA20	1.76%	SMA50	-0.56%	SMA200	-35.72%	Trades		Volume	635	Change	1.42%

Mar-20-24 08:30AM	CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration (ACCESSWIRE) -5.60%
Mar-18-24 06:00AM	CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies (GlobeNewswire) +5.63%
Mar-04-24 05:00AM	CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair (GlobeNewswire)
Jan-29-24 07:00AM	Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire)
Dec-05-23 07:30AM	CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology (PR Newswire)
09:21AM	Loading…
Nov-17-23 09:21AM	CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update (PR Newswire) -8.60%
Nov-14-23 07:47AM	CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (PR Newswire)
Oct-24-23 01:00PM	CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology (ACCESSWIRE) +5.04%
Sep-25-23 07:00AM	Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology (PR Newswire) +6.45%
Aug-29-23 09:00AM	CytoMed Expands Research Collaboration into China After Entering Into MOU (ACCESSWIRE)
Aug-17-23 07:30AM	CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit (Newsfile)
Aug-15-23 01:00PM	CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR T In Vivo Persistency (PR Newswire)
Aug-01-23 07:00AM	Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (PR Newswire)
Jul-27-23 09:00AM	CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology (ACCESSWIRE)
Jul-14-23 10:52AM	Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m (Simply Wall St.)
07:00AM	Loading…
Jul-06-23 07:00AM	A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US (PR Newswire) +6.23%
Jun-28-23 09:00AM	CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology (NewMediaWire) +7.02%
May-11-23 09:00AM	CytoMed Therapeutics to Ring Nasdaq Closing Bell (PR Newswire) -6.31%
May-09-23 10:07AM	CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology (PR Newswire) -19.50%
Apr-13-23 08:00PM	CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PR Newswire)

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GDTC

CytoMed Therapeutics Ltd

Upgrade your FINVIZ experience